価格表

在庫・価格 : 2025年08月29日 17時47分 現在

商品名 商品コード メーカー 包装 価格 在庫 リスト
Anti-TARDBP, Mouse-Mono(2E2-D3) <Anti-TAR DNA Binding Protein>
データシート※最新のデータシートでない場合があります
H00023435-M01 ABNアブノヴァ
Abnova Corporation
100 μg ¥77,000
(未発注)
追加

在庫・価格 : 2025年08月29日 17時47分 現在

Anti-TARDBP, Mouse-Mono(2E2-D3) <Anti-TAR DNA Binding Protein>

  • 商品コード:H00023435-M01
  • メーカー:ABN
  • 包装:100μg
  • 価格: ¥77,000
  • 在庫:無(未発注)
使用文献
No. 文献情報 備考 参照
1 Julien J et al., Methods for Prognostic and/or Diagnostic of Neurodegenerative Disease, Method to Identify Candidate Compounds and Compounds for Treating Neurodegenerative Disease., United States Patent Application. 2016 Mar 31. 20160091504A1

PubMed
2 Mashiko T et al., Developmentally-regulated RNA-binding protein 1 (Drb1)/RNA-binding motif protein 45 (RBM45), a nuclear-cytoplasmic trafficking protein, forms TAR DNA-binding protein 43 (TDP-43)-mediated cytoplasmic aggregates., JBC. 2016 May 12. [Epub a

PubMed
3 Chen W et al., Parkin-mediated reduction of nuclear and soluble TDP-43 reverses behavioral decline in symptomatic mice., Hum. Mol. Genet. (2014) doi: 10.1093/hmg/ddu211

PubMed
4 Garcia Morato J et al. Sirtuin-1 sensitive lysine-136 acetylation drives phase separation and pathological aggregation of TDP-43. Nat Commun 2022 03;13(1):1223
Garcia Morato J et al
2022/01/01
PubMed
5 Pozzi S et al. Monoclonal full-length antibody against TAR DNA binding protein 43 reduces related proteinopathy in neurons. JCI Insight 2020 11;5(21)
Pozzi S et al
2020/01/01
PubMed
6 Tanji K et al. Novel tankyrase inhibitors suppress TDP-43 aggregate formation. Biochem Biophys Res Commun 2021 01;537:85-92
Tanji K et al
2021/01/01
PubMed
7 Pobran TD et al. Aptamer-based enrichment of TDP-43 from human cells and tissues with quantification by HPLC-MS/MS. J Neurosci Methods 2021 11;363:109344
Pobran TD et al
2021/01/01
PubMed
8 Kim G et al. Morphology and Distribution of TDP-43 Pre-inclusions in Primary Progressive Aphasia. J Neuropathol Exp Neurol 2019 03;78(3):229-237
Kim G et al
2019/01/01
PubMed
9 Smeltzer S et al. Hypusination of Eif5a regulates cytoplasmic TDP-43 aggregation and accumulation in a stress-induced cellular model. Biochim Biophys Acta Mol Basis Dis 2021 01;1867(1):165939
Smeltzer S et al
2021/01/01
PubMed
10 Archbold HC et al. TDP43 nuclear export and neurodegeneration in models of amyotrophic lateral sclerosis and frontotemporal dementia. Sci Rep 2018 Mar;8(1):4606
Archbold HC et al
2018/01/01
PubMed
11 Lai CY et al. The D2 Dopamine Receptor Interferes With the Protective Effect of the A<sub>2A</sub> Adenosine Receptor on TDP-43 Mislocalization in Experimental Models of Motor Neuron Degeneration. Front Neurosci 2018;12:187
Lai CY et al
2018/01/01
PubMed
12 Verheijen BM et al. Dysfunction of Protein Quality Control in Parkinsonism-Dementia Complex of Guam. Front Neurol 2018;9:173
Verheijen BM et al
2018/01/01
PubMed
13 Ahmed S et al. <i>MAPT</i> p.V363I mutation: A rare cause of corticobasal degeneration. Neurol Genet 2019 Aug;5(4):e347
Ahmed S et al
2019/01/01
PubMed
14 Kumar S et al. Withaferin-A Treatment Alleviates TAR DNA-Binding Protein-43 Pathology and Improves Cognitive Function in a Mouse Model of FTLD. Neurotherapeutics 2021 01;18(1):286-296
Kumar S et al
2021/01/01
PubMed
15 Pobran TD et al. Detection and characterization of TDP-43 in human cells and tissues by multiple reaction monitoring mass spectrometry. Clin Mass Spectrom 2019 Nov;14 Pt B:66-73
Pobran TD et al
2019/01/01
PubMed
16 Ximelis T et al. Homozygous R136S mutation in PRNP gene causes inherited early onset prion disease. Alzheimers Res Ther 2021 10;13(1):176
Ximelis T et al
2021/01/01
PubMed
17 Liu YJ et al. A system-wide mislocalization of RNA-binding proteins in motor neurons is a new feature of ALS. Neurobiol Dis 2021 12;160:105531
Liu YJ et al
2021/01/01
PubMed
18 Krause K et al. CSF Diagnostics: A Potentially Valuable Tool in Neurodegenerative and Inflammatory Disorders Involving Motor Neurons: A Review. Diagnostics (Basel) 2021 Aug;11(9)
Krause K et al
2021/01/01
PubMed
19 Jamerlan AM et al. A Microplate-Based Approach to Map Interactions between TDP-43 and &#x3B1;-Synuclein. J Clin Med 2022 Jan;11(3)
Jamerlan AM et al
2022/01/01
PubMed
20 . ;

PubMed
21 Koriath CA et al. The clinical, neuroanatomical, and neuropathologic phenotype of <i>TBK1</i>-associated frontotemporal dementia: A longitudinal case report. Alzheimers Dement (Amst) 2017;6:75-81
Koriath CA et al
2017/01/01
PubMed
22 Yang F et al. Evaluation of Breast Cancer Stem Cells and Intratumor Stemness Heterogeneity in Triple-negative Breast Cancer as Prognostic Factors. Int. J. Biol. Sci. 2016;12(12):1568-1577
Yang F et al
2016/01/01
PubMed
23 Nishimura AL et al. Nuclear import impairment causes cytoplasmic trans-activation response DNA-binding protein accumulation and is associated with frontotemporal lobar degeneration. Brain 2010 Jun;133(Pt 6):1763-71
Nishimura AL et al
2010/01/01
PubMed
24 Mashiko T et al. Developmentally Regulated RNA-binding Protein 1 (Drb1)/RNA-binding Motif Protein 45 (RBM45), a Nuclear-Cytoplasmic Trafficking Protein, Forms TAR DNA-binding Protein 43 (TDP-43)-mediated Cytoplasmic Aggregates. J. Biol. Chem. 2016 Jul;291
Mashiko T et al
2016/01/01
PubMed
25 Liu T et al. Modulation of synaptic plasticity, motor unit physiology, and TDP-43 pathology by CHCHD10. Acta Neuropathol Commun 2022 Jul;10(1):95
Liu T et al
2022/01/01
PubMed
26 Cooper-Knock J et al. Atypical TDP-43 protein expression in an ALS pedigree carrying a p.Y374X truncation mutation in TARDBP. Brain Pathol 2023 Jan;33(1):e13104
Cooper-Knock J et al
2023/01/01
PubMed
27 Gelpi E et al. Sporadic Creutzfeldt-Jakob disease VM1: phenotypic and molecular characterization of a novel subtype of human prion disease. Acta Neuropathol Commun 2022 Aug;10(1):114
Gelpi E et al
2022/01/01
PubMed
28 Takeuchi T et al. Sustained therapeutic benefits by transient reduction of TDP-43 using ENA-modified antisense oligonucleotides in ALS/FTD mice. Mol Ther Nucleic Acids 2023 Mar;31:353-366
Takeuchi T et al
2023/01/01
PubMed
29 Koopman M et al. Neuronal overexpression of hTDP-43 in <i>Caenorhabditis elegans</i> mimics the cellular pathology commonly observed in TDP-43 proteinopathies. MicroPubl Biol 2023;2023
Koopman M et al
2023/01/01
PubMed
30 Ayodeji SA et al. Hyperglycemia and O-GlcNAc transferase activity drive a cancer stem cell pathway in triple-negative breast cancer. Cancer Cell Int 2023 May;23(1):102
Ayodeji SA et al
2023/01/01
PubMed
31 H辰nninen JJ et al. Neuropathological findings in possible normal pressure hydro-cephalus: A post-mortem study of 29 cases with lifelines. Free Neuropathol 2022 Jan;3
H辰nninen JJ et al
2022/01/01
PubMed
32 Mamontova EM et al. FUS RRM regulates poly(ADP-ribose) levels after transcriptional arrest and PARP-1 activation on DNA damage. Cell Rep 2023 Oct;42(10):113199
Mamontova EM et al
2023/01/01
PubMed
33 Zeballos C MA et al. Mitigating a TDP-43 proteinopathy by targeting ataxin-2 using RNA-targeting CRISPR effector proteins. Nat Commun 2023 Oct;14(1):6492
Zeballos C MA et al
2023/01/01
PubMed
  • No.: 1
  • 文献情報:
    Julien J et al., Methods for Prognostic and/or Diagnostic of Neurodegenerative Disease, Method to Identify Candidate Compounds and Compounds for Treating Neurodegenerative Disease., United States Patent Application. 2016 Mar 31. 20160091504A1

  • 備考:
  • 参照:
    PubMed
  • No.: 2
  • 文献情報:
    Mashiko T et al., Developmentally-regulated RNA-binding protein 1 (Drb1)/RNA-binding motif protein 45 (RBM45), a nuclear-cytoplasmic trafficking protein, forms TAR DNA-binding protein 43 (TDP-43)-mediated cytoplasmic aggregates., JBC. 2016 May 12. [Epub a

  • 備考:
  • 参照:
    PubMed
  • No.: 3
  • 文献情報:
    Chen W et al., Parkin-mediated reduction of nuclear and soluble TDP-43 reverses behavioral decline in symptomatic mice., Hum. Mol. Genet. (2014) doi: 10.1093/hmg/ddu211

  • 備考:
  • 参照:
    PubMed
  • No.: 4
  • 文献情報:
    Garcia Morato J et al. Sirtuin-1 sensitive lysine-136 acetylation drives phase separation and pathological aggregation of TDP-43. Nat Commun 2022 03;13(1):1223
    Garcia Morato J et al
    2022/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 5
  • 文献情報:
    Pozzi S et al. Monoclonal full-length antibody against TAR DNA binding protein 43 reduces related proteinopathy in neurons. JCI Insight 2020 11;5(21)
    Pozzi S et al
    2020/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 6
  • 文献情報:
    Tanji K et al. Novel tankyrase inhibitors suppress TDP-43 aggregate formation. Biochem Biophys Res Commun 2021 01;537:85-92
    Tanji K et al
    2021/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 7
  • 文献情報:
    Pobran TD et al. Aptamer-based enrichment of TDP-43 from human cells and tissues with quantification by HPLC-MS/MS. J Neurosci Methods 2021 11;363:109344
    Pobran TD et al
    2021/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 8
  • 文献情報:
    Kim G et al. Morphology and Distribution of TDP-43 Pre-inclusions in Primary Progressive Aphasia. J Neuropathol Exp Neurol 2019 03;78(3):229-237
    Kim G et al
    2019/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 9
  • 文献情報:
    Smeltzer S et al. Hypusination of Eif5a regulates cytoplasmic TDP-43 aggregation and accumulation in a stress-induced cellular model. Biochim Biophys Acta Mol Basis Dis 2021 01;1867(1):165939
    Smeltzer S et al
    2021/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 10
  • 文献情報:
    Archbold HC et al. TDP43 nuclear export and neurodegeneration in models of amyotrophic lateral sclerosis and frontotemporal dementia. Sci Rep 2018 Mar;8(1):4606
    Archbold HC et al
    2018/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 11
  • 文献情報:
    Lai CY et al. The D2 Dopamine Receptor Interferes With the Protective Effect of the A<sub>2A</sub> Adenosine Receptor on TDP-43 Mislocalization in Experimental Models of Motor Neuron Degeneration. Front Neurosci 2018;12:187
    Lai CY et al
    2018/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 12
  • 文献情報:
    Verheijen BM et al. Dysfunction of Protein Quality Control in Parkinsonism-Dementia Complex of Guam. Front Neurol 2018;9:173
    Verheijen BM et al
    2018/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 13
  • 文献情報:
    Ahmed S et al. <i>MAPT</i> p.V363I mutation: A rare cause of corticobasal degeneration. Neurol Genet 2019 Aug;5(4):e347
    Ahmed S et al
    2019/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 14
  • 文献情報:
    Kumar S et al. Withaferin-A Treatment Alleviates TAR DNA-Binding Protein-43 Pathology and Improves Cognitive Function in a Mouse Model of FTLD. Neurotherapeutics 2021 01;18(1):286-296
    Kumar S et al
    2021/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 15
  • 文献情報:
    Pobran TD et al. Detection and characterization of TDP-43 in human cells and tissues by multiple reaction monitoring mass spectrometry. Clin Mass Spectrom 2019 Nov;14 Pt B:66-73
    Pobran TD et al
    2019/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 16
  • 文献情報:
    Ximelis T et al. Homozygous R136S mutation in PRNP gene causes inherited early onset prion disease. Alzheimers Res Ther 2021 10;13(1):176
    Ximelis T et al
    2021/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 17
  • 文献情報:
    Liu YJ et al. A system-wide mislocalization of RNA-binding proteins in motor neurons is a new feature of ALS. Neurobiol Dis 2021 12;160:105531
    Liu YJ et al
    2021/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 18
  • 文献情報:
    Krause K et al. CSF Diagnostics: A Potentially Valuable Tool in Neurodegenerative and Inflammatory Disorders Involving Motor Neurons: A Review. Diagnostics (Basel) 2021 Aug;11(9)
    Krause K et al
    2021/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 19
  • 文献情報:
    Jamerlan AM et al. A Microplate-Based Approach to Map Interactions between TDP-43 and &#x3B1;-Synuclein. J Clin Med 2022 Jan;11(3)
    Jamerlan AM et al
    2022/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 20
  • 文献情報:
    . ;

  • 備考:
  • 参照:
    PubMed
  • No.: 21
  • 文献情報:
    Koriath CA et al. The clinical, neuroanatomical, and neuropathologic phenotype of <i>TBK1</i>-associated frontotemporal dementia: A longitudinal case report. Alzheimers Dement (Amst) 2017;6:75-81
    Koriath CA et al
    2017/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 22
  • 文献情報:
    Yang F et al. Evaluation of Breast Cancer Stem Cells and Intratumor Stemness Heterogeneity in Triple-negative Breast Cancer as Prognostic Factors. Int. J. Biol. Sci. 2016;12(12):1568-1577
    Yang F et al
    2016/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 23
  • 文献情報:
    Nishimura AL et al. Nuclear import impairment causes cytoplasmic trans-activation response DNA-binding protein accumulation and is associated with frontotemporal lobar degeneration. Brain 2010 Jun;133(Pt 6):1763-71
    Nishimura AL et al
    2010/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 24
  • 文献情報:
    Mashiko T et al. Developmentally Regulated RNA-binding Protein 1 (Drb1)/RNA-binding Motif Protein 45 (RBM45), a Nuclear-Cytoplasmic Trafficking Protein, Forms TAR DNA-binding Protein 43 (TDP-43)-mediated Cytoplasmic Aggregates. J. Biol. Chem. 2016 Jul;291
    Mashiko T et al
    2016/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 25
  • 文献情報:
    Liu T et al. Modulation of synaptic plasticity, motor unit physiology, and TDP-43 pathology by CHCHD10. Acta Neuropathol Commun 2022 Jul;10(1):95
    Liu T et al
    2022/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 26
  • 文献情報:
    Cooper-Knock J et al. Atypical TDP-43 protein expression in an ALS pedigree carrying a p.Y374X truncation mutation in TARDBP. Brain Pathol 2023 Jan;33(1):e13104
    Cooper-Knock J et al
    2023/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 27
  • 文献情報:
    Gelpi E et al. Sporadic Creutzfeldt-Jakob disease VM1: phenotypic and molecular characterization of a novel subtype of human prion disease. Acta Neuropathol Commun 2022 Aug;10(1):114
    Gelpi E et al
    2022/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 28
  • 文献情報:
    Takeuchi T et al. Sustained therapeutic benefits by transient reduction of TDP-43 using ENA-modified antisense oligonucleotides in ALS/FTD mice. Mol Ther Nucleic Acids 2023 Mar;31:353-366
    Takeuchi T et al
    2023/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 29
  • 文献情報:
    Koopman M et al. Neuronal overexpression of hTDP-43 in <i>Caenorhabditis elegans</i> mimics the cellular pathology commonly observed in TDP-43 proteinopathies. MicroPubl Biol 2023;2023
    Koopman M et al
    2023/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 30
  • 文献情報:
    Ayodeji SA et al. Hyperglycemia and O-GlcNAc transferase activity drive a cancer stem cell pathway in triple-negative breast cancer. Cancer Cell Int 2023 May;23(1):102
    Ayodeji SA et al
    2023/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 31
  • 文献情報:
    H辰nninen JJ et al. Neuropathological findings in possible normal pressure hydro-cephalus: A post-mortem study of 29 cases with lifelines. Free Neuropathol 2022 Jan;3
    H辰nninen JJ et al
    2022/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 32
  • 文献情報:
    Mamontova EM et al. FUS RRM regulates poly(ADP-ribose) levels after transcriptional arrest and PARP-1 activation on DNA damage. Cell Rep 2023 Oct;42(10):113199
    Mamontova EM et al
    2023/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 33
  • 文献情報:
    Zeballos C MA et al. Mitigating a TDP-43 proteinopathy by targeting ataxin-2 using RNA-targeting CRISPR effector proteins. Nat Commun 2023 Oct;14(1):6492
    Zeballos C MA et al
    2023/01/01
  • 備考:
  • 参照:
    PubMed